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Rheumatoid arthritis (RA) is a chronic inflammatory disorder, characterized by a per-
sistent immune cell infiltrate in the synovium accompanied by high levels of inflammatory 
mediators and synovial hyperplasia. Despite significant therapeutic advances, RA 
remains an important unmet medical need. To discover potential new genes controlling 
inflammation and apoptosis in synoviocytes, genes induced by the two pro-inflammatory 
cytokines, tumor necrosis factor α (TNF-α) and interleukin 17A (IL-17A), were systemat-
ically searched. We identified Amphoterin-induced gene and ORF 2 (Amigo-2), a novel 
antiapoptotic adhesion molecule, as synergistically upregulated by the IL-17A/TNF 
combination specifically in RA synoviocytes. In addition, when RA synoviocytes were 
cocultured with immune cells, Amigo2 expression was significantly increased in both 
fibroblasts and immune cells. This induction persisted in RA synoviocytes even after the 
removal of the immune cells. Amigo2 induction was ERK-dependent and on the contrary, 
inhibited by JNK. Furthermore, Amigo2 expression levels correlated with apoptosis of 
the cells when exposed to the proapoptotic agent cadmium (Cd). Interestingly, exposure 
of the cells to HMGB1 in inflammatory conditions increased synergistically Amigo2 
expression and significantly reduced Cd-mediated cellular toxicity. Our findings support 
a model whereby cell–cell contact with immune cells and exposure to the combination of 
both inflammatory cytokines and HMGB1 in the joints of RA patients increases Amigo2 
expression in synoviocytes in an ERK-dependent manner which, in turn, enhances 
cellular adhesion and promotes cell survival and cellular proliferation.
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inTrODUcTiOn
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovium hyper-
plasia leading to progressive joint destruction and bone resorption (1, 2). The synoviocytes present 
in the synovial intimal lining are key contributors to RA pathogenesis. They produce cytokines 
that perpetuate inflammation and secrete proteases contributing to cartilage destruction. Their 
excessive proliferation and apoptosis resistance are the cause of the synovial hypertrophy and their 
migratory and invasive properties exacerbate joint damage (3). So far, treatment of RA is based on 
targeting the immune system with no direct effect on synoviocytes. Removing the hypertrophic 
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pathologic synovial tissue by surgical, chemical, or radiation 
relieves arthritis for a more prolonged time but is complex to 
use in a polyarticular situation (4, 5). Therefore, new molecules 
controlling synovial hyperplasia need to be discovered for 
the development of more synoviocyte-targeted therapeutic 
solutions.
The two pro-inflammatory cytokines tumor necrosis factor α 
(TNF-α) and interleukin 17A (IL-17A) are important contribu-
tors to RA chronicity. They both induce the production of several 
inflammatory mediators in the diseased synovium. Furthermore, 
these two cytokines synergize to induce several antiapoptotic 
molecules in RA synoviocytes (6–10) and a large amount of 
neutrophilic mediators, perpetuating the primary inflammatory 
response (7, 10–13). To discover new apoptosis and inflammatory 
regulators in RA synoviocytes, we searched for genes induced by 
the pro-inflammatory cytokines TNF-α and IL-17A in a previ-
ously performed 12-h transcriptomics analysis. We identified 
Amphoterin-induced gene and ORF 2 (Amigo-2), which was 
synergistically up-regulated by the IL-17A/TNF combination.
Amigo2, also known as Alivin-1, is part of a novel family 
of genes encoding for type I transmembrane proteins with two 
other members, namely AMIGO and AMIGO-3. All AMIGOs 
share a similar protein structure composed of an extracellular 
domain containing six leucine-rich repeats (LRRs) mediating 
cell–cell interaction followed by an immunoglobulin domain, 
a transmembrane domain and an intracellular domain with 
several  possible phosphorylation sites. They form homo- and 
 heterodimers and potentially lead to signal transduction in the 
cells (14, 15). Interestingly, AMIGO-2 was shown to inhibit 
 apoptosis and to promote the survival of electrical active neuronal 
cells (16). AMIGO-2 also increased the migration and invasion 
capacities of gastric cancer cells. Stable AMIGO-2 knockdown in 
gastric adenocarcinoma cells affected the morphology, the ploidy, 
the chromosomal stability and the cellular adhesion and migra-
tion of the cells and almost completely abrogated tumorigenicity 
in nude mice (17). In addition, the closely related family member 
AMIGO was found to be induced by the heparin-binding protein 
amphoterin, also known as HMGB1 (14). Excessive extracellular 
HMGB1 levels have been detected in joints and serum of RA 
patients with higher levels found in the regions where prolifer-
ating synovial tissue invaded cartilage and bone. Furthermore, 
direct injection of HMGB1 into murine knee joints initiated 
persistent inflammatory responses and synovitis and antagonistic 
HMGB1 therapies ameliorated arthritis (18).
In this study, we showed that the IL-17A/TNF combination 
synergistically increased Amigo2 expression specifically in RA 
synoviocytes. Amigo2 was also upregulated when RA synoviocytes 
were cocultured with peripheral blood mononuclear cells (PBMC) 
in both cell types and this induction persisted in RA synoviocytes 
even after the removal of the immune cells. Furthermore, we 
demonstrated that the IL-17A/TNF-mediated Amigo2 induction 
was promoted by ERK and by HMGB1 but was inhibited by JNK. 
In addition, Amigo2 expression levels correlated with apoptosis 
of the cells when exposed to the proapoptotic agent Cd- and 
HMGB1-mediated Amigo2 induction protected the cells against 
Cd toxicity in inflammatory conditions. In conclusion, our study 
showed, for the first time, that cell–cell contact with immune cells 
and exposure to the combination of both inflammatory cytokines 
and HMGB1 increases the expression of the gene Amigo2 in RA 
synoviocytes, which promotes cell survival.
MaTerials anD MeThODs
isolation and culture of synoviocytes
Synoviocytes were grown from synovial tissue samples obtained 
from healthy donors or patients suffering from osteoarthritis 
or RA undergoing joint surgery. Each individual signed an 
informed consent and the protocol was approved by the commit-
tee for protection of persons participating in biomedical research 
under the number AC-2010-11-64. The RA patients fulfilled the 
American College of Rheumatology criteria for RA (19). Briefly, 
synovial tissue was minced in small pieces which were allowed 
to adhere on plastic plates. Those samples were maintained in 
DMEM medium (Eurobio, Courtaboeuf, France) supplemented 
with 10% FBS (Life Technologies), 2% Penicillin–Streptomycin 
(Eurobio), 1% l-glutamine (Eurobio), and 1% Amphotericin B 
(Eurobio) until cells grew out of the tissue and colonized the 
plastic dishes. After cells reached confluence, tissue pieces were 
removed, and cells were trypsinized. Synoviocytes were used 
between passages 4 and 9.
culture conditions
Cells were exposed to IL-17A 50  ng/mL (R&D systems, 
Minneapolis, MN, USA), TNF-α 0.5 ng/mL (R&D systems), or a 
combination of both cytokines. Exposure to the apoptotic agent, 
cadmium 0.1  ppm (kindly provided by Pr. Albarède, Geology 
laboratory, ENS, Lyon, France), was performed after treating 
the cells overnight with a combination of IL-17A and TNF-α or 
with the vehicle. HMGB1 exposure at 50 ng/mL (R&D systems) 
was done in the presence or not of the combined IL-17A/TNF-α 
treatment. Exposures to the mitogen-activated protein kinases 
(MAPKs) inhibitors SP6000125 30 μM (Calbiochem), SB203580 
5 μM (Calbiochem), and U0126 50 μM (Calbiochem) were done 
1 h prior cytokine addition. Cells were treated for 12 or 6 h for 
mRNA extraction or several days for the functional assays.
cocultures of synoviocytes and 
Peripheral Blood Mononuclear cells
Peripheral blood mononuclear cells from healthy donors were 
separated by Ficoll-Hypaque density-gradient centrifugation. 
PBMC were cultured in complete RPMI medium (Eurobio) 
supplemented with 10% AB-human serum (Invitrogen, Saint 
Aubin, France), 2% Penicillin–Streptomycin (Eurobio), and 
1% l-glutamine (Eurobio). Cocultures were performed in flat-
bottomed 96-well culture plates in which 104 synoviocytes/well 
were seeded and allowed to adhere to the plate for several hours. 
PBMC (5 ×  104) were then added to the synoviocytes in the 
presence or not of 5  ug/mL phytohemagglutinin (PHA, Sigma 
Aldrich, Saint-Quentin Fallavier, France). After 24  h, superna-
tants were collected and cells were washed with PBS, followed by 
partial separation of PBMC from synoviocytes by incubating the 
cocultures with a 1 mM EDTA–PBS solution at 37°C for a brief 
time. PBMC present in the EDTA wash and synoviocytes still 
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attached on the plate layer were then lysed for the 24 h timepoint. 
Complete RPMI medium in the presence or not of PHA was then 
added to the cells for 24 or 48 h more before collection of the 
supernatants and lysis of the cells. For each condition, twelve 
wells were combined in order to obtain sufficient material to 
perform gene expression quantifications.
cell Death assays
Cell death was determined by flow cytometry and cell cycle 
analysis. Cell cycle analysis was performed by fixating the cells 
in ethanol during at least 24  h and by subsequent staining of 
the cells with 3.3 μM of 4,6-diamidino-2-phenylindole (DAPI). 
Fluorescence was analyzed on a Navios flow cytometer (Beckman 
Coulter, Brea, CA, USA), and the amount of dead cells in sub-
G0/G1 was determined using the Kaluza® flow analysis software 
(Beckman Coulter, Brea, CA, USA).
Quantitative real-time Pcr
Total RNA was isolated from cells using an RNeasy® Mini kit 
(Qiagen, Hilden, GE) according to the manufacturer’s protocol. 
cDNA was synthesized using the QuantiTect reverse transcription 
kit (Qiagen) following manufacturer’s instructions. Reactions 
were performed on the CFX96 Real-Time PCR Detection System 
(Biorad, Marnes-la-Coquette, France) using the QuantiFast 
SYBR green kit and the Qiagen QuantiTect primers (QT01034817 
for Amigo2, QT00025011 for Bcl2, QT00001792 for CD3 and 
QT01192646 for GAPDH). Cycle threshold (Ct) values were 
normalized to the expression levels of the housekeeping gene 
GAPDH. The relative expression of the genes in treated cells 
versus control cells was determined using the ΔCt method.
elisa
Tumor necrosis factor α and IL-17A production (R&D system) 
were quantified in the supernatants of exposed synoviocytes or 
of cocultures after the indicated culture duration and according 
to the manufacturer’s instructions. Absorbance at 450  nm was 
measured using the multilabel plate reader VICTOR™ X4 (by 
Perkin Elmer, Waltham, MA, USA), and results were obtained by 
subtracting the background read at 540 nm.
statistical analyses
All data are expressed as mean ± SEM. RT-PCR data were log2 
transformed before statistical analyses. Statistical significance 
was determined by GraphPad Prism using a two-way Annova 
with Bonferroni posttests. The level of confidence is represented 
by P-values indicated in the figures.
resUlTs
amigo2 is Upregulated More specifically 
in ra synoviocytes in inflammatory 
conditions
To identify new inflammatory and apoptosis regulators in 
RA synoviocytes, genes induced by the pro-inflammatory 
cytokines TNF-α and IL-17A were systematically searched. To 
do so, a microarray dataset previously validated and derived 
from RA synoviocytes exposed for 12  h to TNF-α, IL-17A, or 
their combination was used. In this microarray, 130 genes were 
synergistically regulated by the combination of IL-17A and 
TNF (20, 21). Among these synergistically regulated genes, four 
genes were involved in apoptosis regulation. However, three of 
these genes were barely expressed in RA synoviocytes. The gene 
Amigo2 was therefore identified as the only apoptotic regulator 
sufficiently expressed and synergistically upregulated with the 
IL-17A/TNF combination (Figure 1A). This cytokine-mediated 
upregulation was specific to Amigo2 as compared to the other 
family member Amigo3, which did not get modulated by neither 
the cytokines alone nor their combination (Figure 1B). Amigo1 
probeset was not present in the microarray dataset; therefore, its 
expression in inflammatory conditions could not be verified in 
RA synoviocytes.
The regulatory effect of IL-17A and TNF-α on Amigo2 expres-
sion was validated by RT-PCR and showed that the gene is already 
upregulated by TNF-α and IL-17A alone and that their combina-
tion synergistically upregulates its expression to up to sevenfold 
in RA synoviocytes (Figure  1C). In order to know whether 
this Amigo2 upregulation was specific to RA synoviocytes, its 
expression was also examined in synoviocytes originating from 
healthy donors and OA patients. In control situation, Amigo2 
expression was higher in RA synoviocytes than in OA and 
healthy synoviocytes (Figure 1D). Furthermore, when cells were 
exposed to the IL-17A/TNF combination, a significant higher 
gene induction was observed in RA synoviocytes (ninefold) in 
comparison to both healthy and OA synoviocytes (fourfold and 
twofold, respectively, Figure 1D). These results demonstrate that 
Amigo2 induction in inflammatory conditions is more specific 
to RA synoviocytes.
coculture of ra synoviocytes with 
immune cells increases amigo2 
expression in Both cell Types
In order to better mimick the in  vivo inflammatory situation 
where synoviocytes interact with immune cells, Amigo2 gene 
expression was also evaluated in RA synoviocytes cocultured 
with PBMC activated or not with PHA. Before lysis of the cells 
for RNA extraction, PBMC were separated from synoviocytes 
with EDTA in order to quantify Amigo2 expression only in 
the synoviocytes or the PBMC alone and not in the mixture of 
synoviocytes with PBMC. However, PBMC were only partially 
removed as measured by the expression of CD3, a marker present 
on the surface of T lymphocytes (Figure S1 in Supplementary 
Material). Coculture of RA synoviocytes with resting PBMC for 
24 h already significantly induced Amigo2 gene expression to up 
to fivefold (Figure 2A). This Amigo2 induction was most likely 
triggered only by cell–cell contact since no significant IL-17A 
(Figure  2C) and TNF-α (Figure  2D) secretion occurred. In 
synoviocytes cocultured for 24 h with activated PBMC, Amigo2 
gene expression was enhanced (up to 10-fold) (Figure 2A) with 
an increased secretion of IL-17A (Figure 2C). The production of 
TNF-α, however, did not change after PHA stimulation in com-
parison to the control situation (Figure 2D). Changes in amigo2 
expression were seen in PBMC cocultured with RA synoviocytes 
FigUre 1 | amigo2 is upregulated more specifically in ra synoviocytes in inflammatory conditions. Synoviocytes were exposed to IL-17A or TNF-α alone 
or to a combination of both for 12 h. Amigo2 and Amigo3 expressions were assessed by transcriptomic analysis (a,B) and Amigo2 expression was also assessed 
by quantitative real-time PCR (c,D). Gene expression was compared between the different treatments and is represented as fold changes compared to control in 
RA synoviocytes (a–c). Amigo2 expression was also evaluated in synoviocytes from different clinical settings (healthy, OA and RA) and is expressed as fold changes 
compared to healthy synoviocytes exposed to vehicle (D). Data are the mean of at least three independent experiments ± SEM. #Comparison with control situation, 
*comparison between different cytokine combinations (c) or between cell types (D). *P ≤ 0.05, **P ≤ 0.01, ***, ###P ≤ 0.001.
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in control condition with a high level of variability between 
PBMC donors (Figure  2B). PHA stimulation did not affect 
Amigo2 expression (Figure  2B) in PBMC cocultured with RA 
synoviocytes in comparison to the control situation. These results 
indicate that the cellular interactions between RA synoviocytes 
and immune cells trigger the induction of Amigo2 expression in 
both synoviocytes and PBMC.
amigo2 induction in ra synoviocytes 
cocultured with immune cells remains 
stable even after immune cell removal
Since RA synoviocytes have been described to retain their aggres-
sive phenotype months after removal from the RA synovial milieu 
(3, 22, 23), the induction of Amigo2 expression was evaluated 
in the cocultures over time after removing the immune cells at 
24 h. When RA synoviocytes were cocultured with resting PBMC, 
Amigo2 expression was enhanced at 24 h to up to 5-fold and its 
expression continued to raise to more than 10-fold even after par-
tial PBMC removal (Figure 3A). This increase in Amigo2 expres-
sion occurred despite the barely detectable levels of both IL-17A 
(Figure 3B) and TNF-α (Figure 3C) after partial PBMC removal. 
However, at 72 h Amigo2 expression dropped back to the levels 
observed at 24 h (fivefold, Figure 3A). In the cocultures of RA 
synoviocytes with activated PBMC, Amigo2 expression increased 
to almost 15-fold after 24 h and slowly decreased over time after 
PBMC removal (Figure 3A). At 72 h, Amigo2 expression levels 
had a tendency although not significant to remain higher than the 
ones observed with the cocultures performed with resting PBMC 
(10-fold versus 5-fold, respectively, Figure  3A). These results 
indicate that induction of Amigo2 expression in RA synoviocytes 
that have been in contact with activated immune cells remains 
even in the absence of the cellular interaction and the inflamma-
tory environment.
amigo2 expression is regulated by 
MaPKs and hMgB1 in inflammatory 
conditions
Since nothing is known yet about the regulation of Amigo2 
expression in synoviocytes, the implication of several potential 
regulators was investigated. It was previously reported that 
MAPKs are involved in the regulation of several processes in 
RA synoviocytes including apoptosis (24), and their role in 
the signaling cascade of Amigo2 is yet unknown. Therefore, 
the effect of the three MAPKs c-jun N-terminal kinase (JNK), 
extracellular signal regulated kinase (ERK), and p38 on Amigo2 
expression was examined by inhibiting them 1 h prior the addi-
tion of cytokines. JNK inhibition led to a significant induction 
in Amigo2 expression already in control conditions (fourfold), 
which was enhanced to up to eightfold in the presence of 
cytokines (Figure 4A). On the contrary, ERK inhibition led to 
a decrease in Amigo2 expression in control condition and com-
pletely abrogated the cytokine-mediated induction in Amigo2 
FigUre 2 | coculture of ra synoviocytes with immune cells increases 
amigo2 expression in both cell types. RA synoviocytes were cocultured 
with PBMC from healthy donors in the presence or not of PHA for 24 h. In 
the cocultures, PBMC were separated from synoviocytes by EDTA addition 
prior cell lysis. Amigo2 expression was assessed by quantitative real-time 
PCR and was expressed as fold changes compared to synoviocytes cultured 
alone and exposed to vehicle (a,B). Amigo2 expression was evaluated in 
both synoviocytes (a) and PBMC (B) cultured alone or together. The 
production of IL-17A (c) and TNF-α (D) by the cocultures was quantified by 
ELISA. The production of these cytokines was not detectable in synoviocytes 
cultured alone. Data are the mean of at least three independent 
experiments ± SEM. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001.
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expression (Figure  4A). p38 inhibition did not affect Amigo2 
expression (Figure 4A), indicating that it is not involved in the 
regulation of its expression. These results demonstrate that JNK 
and ERK regulate Amigo2 expression in opposite manners with 
JNK acting as an inhibitor of Amigo2 expression and ERK acting 
as an activator.
The related family member AMIGO was first discovered in 
a systematic screen searching for genes induced on HMGB1-
coated matrix (15). Since HMGB1 has been implicated in 
RA pathogenesis, the regulation of Amigo2 by HMGB1 was 
investigated in RA synoviocytes. Amigo2 expression was there-
fore quantified after exposure of the cells for 12 h to HMGB1 
alone or in combination with IL-17A and TNF-α. HMGB1 
alone increased Amigo2 expression to more than threefold 
(Figure  4B). Furthermore, the combination of both HMGB1 
and cytokines led to a significant synergistic induction (39-fold, 
Figure  4B). These results demonstrate that alike the closely 
related family member Amigo, Amigo2 expression is regulated 
by HMGB1, and that HMGB1 can synergize with cytokines to 
further enhance its expression.
amigo2 expression levels correlate 
with cell Death
Since Amigo2 is involved in the survival of other cell types (20, 21), 
the correlation between its expression and the apoptosis outcome 
of the cells was investigated. Synoviocytes from different clinical 
settings were treated with a combination of TNF-α and IL-17A 
followed by their exposure to a low dose of the cytotoxic agent 
cadmium (Cd). Preliminary experiments indicated that Cd could 
induce significant apoptosis at concentration as low as 0.1 ppm 
in inflammatory conditions. Amigo2 gene expression was then 
evaluated after a 6-h exposure to Cd (Figure 5A), a time point at 
which cell death did not yet occur, and cell death was evaluated 
after a week (Figure 5B). As demonstrated before, Amigo2 induc-
tion with cytokines was significantly higher in RA synoviocytes 
than in healthy and OA synoviocytes (Figure  5A). Exposure 
of the synoviocytes to Cd alone did not affect Amigo2 expres-
sion (Figure 5A) and did not induce any significant cell death 
(Figure 5B). Interestingly, Cd significantly inhibited the cytokine-
mediated Amigo2 induction in both OA and RA synoviocytes 
(Figure 5A). This corroborated with an increased cell death in 
cells exposed to Cd in inflammatory conditions (Figure  5B). 
Healthy synoviocytes presented a slight Amigo2 induction with 
cytokines, which was not affected by Cd (Figure 5A). However, 
Amigo2 expression levels were as low as the ones observed in 
OA and RA synoviocytes, which could explain their sensitivity 
to Cd-induced toxicity in inflammatory conditions (Figure 5B). 
These results indicate that cell death correlates with the expres-
sion levels of the antiapoptotic gene Amigo2 in synoviocytes. The 
involvement of Bcl2 in the cell death outcome was also explored. 
Bcl2 expression was increased significantly with the cytokine 
combination only in OA synoviocytes (Figure 5D). However, no 
difference was observed in Bcl2 expression in synoviocytes from 
the different clinical settings when exposed to Cd in the presence 
of cytokines (Figure 5D). These results indicate that Bcl2 is not 
involved in the resistance to Cd-induced apoptosis in inflamma-
tory conditions.
Since Amigo2 expression levels correlated with cell death, the 
effect of HMGB1 in inflammatory conditions was also evalu-
ated at the cell death level. RA synoviocytes were preexposed to 
HMGB1 alone or in combination with cytokines overnight fol-
lowed by Cd addition, and cell death was evaluated after a week. 
Addition of HMGB1 is reduced by half the Cd-induced apoptosis 
in inflammatory conditions (Figure 5C). These data indicate that 
HMGB1 protects RA synoviocytes against Cd-induced apoptosis 
in inflammatory conditions in part by upregulating Amigo2 
expression.
DiscUssiOn
Despite the variety of current treatments in use for RA, none of 
them completely cure it but rather slow the progression of the 
symptoms. Indeed, RA pathogenesis is complex and involves 
many cell types including several immune cells as well as the 
FigUre 4 | amigo2 expression is regulated by MaPKs and hMgB1. RA synoviocytes were preexposed to MAPKs inhibitors for 1 h followed by the addition of 
a combination of IL-17A and TNF-α (a) or co-exposed to HMGB1 and the TNF/IL-17A combination (B). After 12 h, Amigo2 expression was assessed by 
quantitative real-time PCR and is expressed as fold changes compared to control situation. SP6000125, JNK inhibitor; SB203580, p38 inhibitor; U0125, ERK 
inhibitor; Ctl, control; Cyt, cytokines; H, HMGB1. Data are the mean of at least three independent experiments ± SEM. #Comparison with control situation, 
*comparison with cytokine-treated cells. *,#P ≤ 0.05, **P ≤ 0.01.
FigUre 3 | amigo2 induction in ra synoviocytes cocultured with immune cells remains stable even after immune cell removal. RA synoviocytes were 
cocultured with PBMC from healthy donors in the presence or not of PHA for 24 h. In the cocultures, PBMC were separated from synoviocytes by EDTA addition. 
Synoviocytes were cultured for 24 or 48 h more after PBMC removal. Amigo2 expression was assessed at different time-points by quantitative real-time PCR and 
was expressed as fold changes compared to RA synoviocytes cultured alone and exposed to vehicle (a). The production of IL-17A (B) and TNF-α (c) by the 
cocultures was quantified by ELISA. The production of these cytokines was measured in cocultures with no immune cell removal (cocultures) or with immune cell 
removal by EDTA (cocultures EDTA). Their production was not detectable in synoviocytes cultured alone. Data are the mean of at least three independent 
experiments ± SEM. #comparison with control situation, *comparison between synoviocytes (a) or PBMC (B) alone and cocultures, §comparison between 
cocultures with or without EDTA addition. *,#,§P ≤ 0.05, **,##,§§P ≤ 0.01, ***, ###P ≤ 0.001.
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resident fibroblasts. These cells play a key role by proliferating 
excessively and by producing cytokines that perpetuate inflam-
mation and proteases that contribute to cartilage destruction. 
In the present study, we systematically searched for genes 
controlling inflammation and apoptosis regulated by the two 
pro-inflammatory cytokines IL-17A and TNF-α in synoviocytes. 
Using this approach, we identified the novel antiapoptotic regula-
tor Amigo2.
FigUre 5 | amigo2 expression levels correlate with cell death. Healthy, OA and RA synoviocytes were preexposed to a combination of IL-17A and TNF-α 
overnight before addition of a low dose of the proapoptotic agent Cd (a,B,D). Amigo2 expression was then evaluated 6 h after Cd addition by quantitative real-time 
PCR and is expressed as fold changes compared to healthy synoviocytes exposed to vehicle (a). Cell death was determined by cell cycle analysis after a week (B). 
To evaluate the effect of HMGB1 on cell death, RA synoviocytes were preexposed to a combination of IL-17A and TNF-α in the presence or not of HMGB1 followed 
by Cd addition. Cell death was quantified by cell cycle analysis after a week and is represented as fold changes compared to cells treated with Cd and 
cytokines (c). Similarly to Amigo2, Bcl2 expression was evaluated by quantitative real-time PCR and is expressed as fold changes compared to healthy 
synoviocytes exposed to vehicle (D). Data are the mean of at least three independent experiments ± SEM. Cyt, cytokines; H, HMGB1. #Comparison with control 
situation, *comparison with cytokine treated cells, §comparison between cell types. *,#P ≤ 0.05, **,§§P ≤ 0.01, ***,###,§§§P ≤ 0.001.
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We demonstrated that Amigo2 expression is regulated by 
several players in RA synoviocytes. First, the combination of 
IL-17A and TNF-α synergistically increased its expression 
specifically in RA synoviocytes. These two cytokines are already 
known to synergize to induce the production of several pro-
inflammatory mediators including IL-6, IL-1β, and IL-8 as well 
as antiapoptotic molecules such as synoviolin in RA synoviocytes 
(4). The underlying molecular mechanisms of such synergy are 
still unclear. One explanation is the ability of IL-17A to stabilize 
posttranscriptionally the mRNA of some of the TNF-induced 
genes (25–29). Another explanation is the enhancing effect of the 
IL-17A/TNF combination on the expression of the TNF type II 
receptor (20). It is not sure which of these mechanisms controls 
the synergistic effect observed on Amigo2 expression.
We also showed that Amigo2 expression was regulated 
in opposite manner by the two MAPKs, JNK and ERK. ERK 
promoted Amigo2 expression while JNK suppressed it. It has 
been previously showed that ERK predominantly regulates RA 
synoviocytes proliferation (30) while JNK controls the expression 
of matrix metalloproteinase 3 (MMP3) in RA synoviocytes and 
thereby joint destruction (31). Therefore, it seems that Amigo2 
expression is tightly regulated by these two MAPKs and we could 
speculate that a small shift in this tight regulation could drive the 
cells toward a specific fate. Increased Amigo2 expression would 
lead to excessive proliferation whereas decreased Amigo2 expres-
sion would promote the invasive phenotype of the cells.
In addition to the MAPKs, we demonstrated that cell–cell 
contact between immune cells and the synoviocytes promoted 
Amigo2 expression in both cell types. This induction was 
further enhanced when the immune cells were activated by 
PHA. We previously revealed that interaction of PBMC with 
RA synoviocytes promoted the activation and expansion of 
Th17 cells through caspase 1 activation (32). Here, we show 
for the first time that cell–cell contact promotes also the 
upregulation of antiapoptotic molecules such as Amigo2. Since 
the cocultures were performed with PBMC, containing various 
types of immune cells, it cannot be sure which immune cells 
express the most Amigo2. It could be that several of them 
express the gene following the example of the antiapoptotic 
mediator synoviolin expressed in both Th17 cells and B cells 
(9). However, this remains to be determined. Interestingly, the 
induction in Amigo2 expression persisted in RA synoviocytes 
even after the partial removal of immune cells. It was already 
shown that RA synoviocytes present imprinted anomalies, 
such as mutations or epigenetic changes (8), and that they can 
destroy human cartilage many months after removal from the 
RA synovial milieu when engrafted into mice with severe com-
bined immunodeficiency (SCID) (19, 25). Here, we show that 
FigUre 6 | Model of the regulation of amigo2 expression which 
promotes cell survival and proliferation. A model was proposed whereby 
cellular interaction with immune cells and exposure of the cells to the 
pro-inflammatory cytokines IL-17A and TNF-α as well as to HMGB1 
increases Amigo2 expression in an ERK-dependent manner leading to 
enhanced cellular adhesion and promoting cell survival and proliferation.
8
Benedetti et al. Amigo-2 in Arthritis Synoviocytes
Frontiers in Immunology | www.frontiersin.org June 2016 | Volume 7 | Article 254
the upregulation in Amigo2 expression after cell–cell contact 
with activated immune cells can be maintained at least until 
more than 72 h. We can therefore speculate that the constant 
cellular interactions between the synoviocytes and the immune 
cells infiltrating the synovium maintain high levels of Amigo2 
in the synoviocytes of RA patients.
Finally, we showed that Amigo2 expression is synergistically 
upregulated by the IL-17A/TNF combination and the heparin-
binding protein HMGB1. HMGB1 is known to be implicated 
in RA pathogenesis. It is present in excessive levels in joints 
and serum of RA patients, and antagonistic HMGB1 therapies 
ameliorate arthritis in murine models (18). HMGB1 induces 
synergistic interactions by forming complexes with certain 
other pro-inflammatory molecules such as lipopolysaccharide 
(LPS) or IL-1β (33). In this study, we showed for the first time 
that HMGB1 also enhances the effect of IL-17A and TNF-α in 
synoviocytes. This enhancing effect is most likely indirect via the 
activation of the toll-like receptors (TLRs) which, in turn, activate 
the transcription factor nuclear factor κ B (NF-κB) leading to the 
transcription of more TNF-α (18).
Furthermore, we demonstrated in this study that Amigo2 
expression levels correlated with the cellular outcome of the 
cells. Indeed, when cells were exposed to the cytotoxic agent 
Cd in inflammatory conditions, Cd inhibited the IL-17A/TNF-
mediated induction in Amigo2, which corroborated with an 
increased apoptosis. Moreover, the increase in Amigo2 expres-
sion by the HMGB1/IL-17-A/TNF combination was correlated 
with a cellular protection against cd-induced toxicity. However, 
the direct effect of Amigo2 on cell survival remains to be proven. 
siRNA-mediated knockdown of Amigo2 in RA synoviocytes only 
led to a 25% knockdown efficiency in our hands and did not affect 
the cellular outcome of the cells (data not shown). AMIGO2 is a 
transmembrane protein known to form homophilic and hetero-
philic interactions with other AMIGO family members (21). It is 
possible that the other members of the family could compensate 
when Amigo2 is partially depleted. Amigo3 was not induced by 
IL-17A and TNF in RA synoviocytes. However, the expression of 
Amigo1 could not be verified as its corresponding probeset was 
not present in the microarray dataset used. Therefore, Amigo1 
could potentially compensate for Amigo2 once depleted. Since 
Amigo2 is an adhesion molecule, we believe that an increase in 
its expression leads to an enhancement in the cell–cell contacts 
protecting the cells against cellular stress and hypoxia and 
promoting cellular proliferation. We suggest a model whereby 
cell–cell contact with immune cells and the presence of pro-
inflammatory cytokines and HMGB1 in the joints of RA patients 
promote Amigo2 expression in an ERK-dependent manner and 
enhance their resistance to apoptosis (Figure 6).
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